{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T09:29:20Z","timestamp":1671010160932},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,4,20]],"date-time":"2010-04-20T00:00:00Z","timestamp":1271721600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s10147-010-0073-6","type":"journal-article","created":{"date-parts":[[2010,4,19]],"date-time":"2010-04-19T04:49:54Z","timestamp":1271652594000},"page":"390-398","source":"Crossref","is-referenced-by-count":3,"title":["Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer"],"prefix":"10.1007","volume":"15","author":[{"given":"Susana M.","family":"Campos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne T.","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leroy M.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig A.","family":"Bunnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle S.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyndsay","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn N.","family":"Krasner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,20]]},"reference":[{"key":"73_CR1","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"14","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT et al (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 14:3312\u20133322","journal-title":"J Clin Oncol"},{"issue":"1","key":"73_CR2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2004.09.046","volume":"96","author":"JT Thigpen","year":"2005","unstructured":"Thigpen JT, Aghajanian CA, Alberts DS et al (2005) Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol 96(1):10\u201318","journal-title":"Gynecol Oncol"},{"issue":"2","key":"73_CR3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1525-1438.2007.01001.x","volume":"18","author":"JV Brown","year":"2008","unstructured":"Brown JV, Rettenmaier MA, Loez KL et al (2008) A phase II, multicenter trial of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum. Int J Gynecol Cancer 18(2):249\u2013254","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"73_CR4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2007.08.062","volume":"108","author":"F Abyshahin","year":"2008","unstructured":"Abyshahin F, Singh DK, Lurain KL et al (2008) Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecol Oncol 108(1):53\u201357","journal-title":"Gynecol Oncol"},{"issue":"2","key":"73_CR5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ygyno.2008.01.039","volume":"109","author":"G Ferrandina","year":"2008","unstructured":"Ferrandina G, Ludovisi M, Corrado G et al (2008) Prognostic role of CA125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol 109(2):187\u2013193","journal-title":"Gynecol Oncol"},{"issue":"19","key":"73_CR6","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","volume":"25","author":"D Mutch","year":"2007","unstructured":"Mutch D, Orlando M et al (2007) Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25(19):2811\u20132818","journal-title":"J Clin Oncol"},{"issue":"6","key":"73_CR7","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/sj.bjc.6602427","volume":"92","author":"M Baur","year":"2005","unstructured":"Baur M, Schernhammer E, Gneist M et al (2005) Phase I\/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer. Br J Cancer 92(6):1019\u20131025","journal-title":"Br J Cancer"},{"issue":"2","key":"73_CR8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","volume":"16","author":"P Rose","year":"1998","unstructured":"Rose P, Blessing JA et al (1998) Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 16(2):405\u2013410","journal-title":"J Clin Oncol"},{"issue":"8","key":"73_CR9","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/07357900801971040","volume":"26","author":"S Campos","year":"2008","unstructured":"Campos S (2008) Anti-epidermal growth factor receptor strategies for advanced breast. Cancer Invest 26(8):757\u2013765","journal-title":"Cancer Invest"},{"key":"73_CR10","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1038\/sj.onc.1204082","volume":"19","author":"J Mendelsohn","year":"2000","unstructured":"Mendelsohn J, Baselga J (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19:6550\u20136565","journal-title":"Oncogene"},{"key":"73_CR11","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/sj.bjc.6601921","volume":"91","author":"B El-Rayes","year":"2004","unstructured":"El-Rayes B, LoRusso T (2004) Targeting the epidermal growth factor receptor. Br J Cancer 91:418\u2013424","journal-title":"Br J Cancer"},{"key":"73_CR12","first-page":"5078","volume":"9","author":"R Nahta","year":"2003","unstructured":"Nahta R, Esteva FJ (2003) Her 2 targeted therapy: lessons learned and future directions. Clin Cancer Res 9:5078\u20135084","journal-title":"Clin Cancer Res"},{"key":"73_CR13","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1126\/science.2422759","volume":"232","author":"AB Schreiber","year":"1986","unstructured":"Schreiber AB, Winkler ME, Derynck R (1986) Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 232:1250\u20131253","journal-title":"Science"},{"key":"73_CR14","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000217979","volume":"17","author":"T Shibata","year":"1996","unstructured":"Shibata T, Kawano T, Nagayasu H et al (1996) Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth. Tumour Biol 17:168\u2013175","journal-title":"Tumour Biol"},{"key":"73_CR15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO;2-7","volume":"184","author":"JS Jong de","year":"1998","unstructured":"de Jong JS, van Diiest PJ, van der Valk P et al (1998) Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. II: correlations with proliferation and angiogenesis. J Path 184:53\u201357","journal-title":"J Path"},{"key":"73_CR16","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1073\/pnas.72.4.1317","volume":"72","author":"S Cohen","year":"1975","unstructured":"Cohen S, Carpenter G (1975) Human epidermal growth factor: isolation and chemical and biological properties. Proc Natl Acad Sci USA 72:1317\u20131321","journal-title":"Proc Natl Acad Sci USA"},{"key":"73_CR17","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3109\/07357909109018953","volume":"9","author":"BW Ennis","year":"1991","unstructured":"Ennis BW, Lippman ME, Dickson RB et al (1991) The EGF receptor system as a target for antitumor therapy. Cancer Invest 9:553\u2013562","journal-title":"Cancer Invest"},{"key":"73_CR18","doi-asserted-by":"crossref","unstructured":"Gholam D, Chebib A, Hauteville D et al (2007) Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor positive, estrogen receptor negative, progesterone receptor-negative and human epidermal growth factor receptor-2 negative (triple negative) breast cancer. Anticancer Drugs 18(7):835\u2013837","DOI":"10.1097\/CAD.0b013e3280adc8e0"},{"issue":"3","key":"73_CR19","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3816\/CBC.2006.n.040","volume":"7","author":"S Modi","year":"2006","unstructured":"Modi S, D\u2019 Andrea G, Norton L et al (2006) A Phase I study of cetuximab\/paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer 7(3):270\u2013277","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"73_CR20","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2003.10.104","volume":"21","author":"MA Bookman","year":"2003","unstructured":"Bookman MA, Darcy KM et al (2003) Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with expression of HER2: a phase II trial of the Gynecological Oncology Group. J Clin Oncol 21(2):282\u2013290","journal-title":"J Clin Oncol"},{"key":"73_CR21","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1525-1438.2007.01144.x","volume":"18","author":"MJ Palayekar","year":"2008","unstructured":"Palayekar MJ, Herzog TJ (2008) The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer. Int J Gynecol Cancer 18:879\u2013890","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"73_CR22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ygyno.2006.10.019","volume":"104","author":"MV Seiden","year":"2007","unstructured":"Seiden MV, Burris MA, Matulonis U et al (2007) A phase II trial of EMD 72000 (Matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol 104(3):727\u2013731","journal-title":"Gynecol Oncol"},{"issue":"1","key":"73_CR23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1158\/1535-7163.MCT-06-0401","volume":"6","author":"P Mullen","year":"2007","unstructured":"Mullen P, Cameron DA, Hasman M et al (2007) Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross talk with estrogen receptor signaling. Mol Cancer Ther 6(1):93\u2013100","journal-title":"Mol Cancer Ther"},{"key":"73_CR24","doi-asserted-by":"crossref","unstructured":"Gordon MS, Mateo D, Aghajanian C et al (2006) Clinical activity of pertuzumab (rhuMAb 2 C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER 2 activation status. J Clin Oncol 24(26):4324\u20134332","DOI":"10.1200\/JCO.2005.05.4221"},{"key":"73_CR25","doi-asserted-by":"crossref","unstructured":"Makhija S, Glenn D, Ueland F et al (2007) Results from a phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. J Clin Oncol; 2007 ASCO annual meeting proceedings, part I, vol 25, no 18S (June 20 Supplement), Abstract 5507","DOI":"10.1200\/jco.2007.25.18_suppl.5507"},{"issue":"11","key":"73_CR26","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones R et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med 344(11):783\u2013792","journal-title":"N Engl J Med"},{"key":"73_CR27","unstructured":"Albain K, Ellefge R, Gradishar W et al (2002) Open label phase II multicenter trial of ZD 1839 (Iressa) in patients with advanced breast cancer (Abstract 20). Breast Cancer Res Treat 76(S1):S33"},{"issue":"suppl 1","key":"73_CR28","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1016\/S1359-6349(03)90469-1","volume":"1","author":"G Minckwitz Von","year":"2003","unstructured":"Von Minckwitz G, Jonat W, Beckman M et al (2003) A multicenter phase II trial to evaluate Gefitinib (\u201cIressa\u201d, ZD1839) (500\u00a0mg\/day) in patients with metastatic breast cancer after previous chemotherapy. Eur J Cancer 1(suppl 1):S133","journal-title":"Eur J Cancer"},{"key":"73_CR29","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1200\/JCO.2005.08.326","volume":"23","author":"J Baselga","year":"2006","unstructured":"Baselga J, Albanell J, Ruiz A et al (2006) Phase II and tumor pharmocodynamic study of Gefitinib (ZD 1839) in patients with advanced breast cancer. J Clin Oncol 23:5323\u20135333","journal-title":"J Clin Oncol"},{"issue":"7","key":"73_CR30","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/cncr.22545","volume":"109","author":"EM Posadas","year":"2007","unstructured":"Posadas EM, Liel MS, Kwitkowski V et al (2007) A phase II and pharmacodynamic tudy of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 109(7):1323\u20131330","journal-title":"Cancer"},{"issue":"1","key":"73_CR31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ygyno.2006.10.053","volume":"105","author":"U Wagner","year":"2007","unstructured":"Wagner U, du Bois A, Pfisterer J et al (2007) Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy\u2014a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol 105(1):132\u2013137","journal-title":"Gynecol Oncol"},{"issue":"suppl 1","key":"73_CR32","first-page":"S115","volume":"76","author":"E Winer","year":"2002","unstructured":"Winer E, Colbeigh M, Dickler M et al (2002) Phase II Multicenter study to evaluate the efficacy and safety of Tarceva (erlotinib, OSAI -774) in women with previously treated locally advanced or metastatic breast cancer (abstract 445). Breast Cancer Res Treat 76(suppl 1):S115","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"73_CR33","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.bjc.6604371","volume":"98","author":"PA Vasey","year":"2008","unstructured":"Vasey PA, Gore M, Wilson R et al (2008) Phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. Br J Cancer 98(11):1774\u20131780","journal-title":"Br J Cancer"},{"issue":"5","key":"73_CR34","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1525-1438.2005.00137.x","volume":"15","author":"AN Gordon","year":"2005","unstructured":"Gordon AN, Finkler N, Edwards RP et al (2005) Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1\/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 15(5):785\u2013792","journal-title":"Int J Gynecol Cancer"},{"issue":"26","key":"73_CR35","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733\u20132743","journal-title":"N Engl J Med"},{"issue":"24","key":"73_CR36","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1200\/JCO.2005.08.091","volume":"23","author":"S Campos","year":"2005","unstructured":"Campos S, Hamid O, Seiden MV et al (2005) Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol 23(24):5597\u20135604","journal-title":"J Clin Oncol"},{"issue":"12","key":"73_CR37","first-page":"4885","volume":"6","author":"FM Sirotnak","year":"2000","unstructured":"Sirotnak FM, Zakowski MF, Miller VA et al (2000) Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by co administration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6(12):4885\u20134892","journal-title":"Clin Cancer Res"},{"key":"73_CR38","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1177\/030089160208800145","volume":"88","author":"F Ciardiello","year":"2002","unstructured":"Ciardiello F, Tortora G, De Placido S et al (2002) ZD1839 (Iressa): preclinical studies and pharmacology. Tumori 88:S155\u2013S157","journal-title":"Tumori"},{"issue":"5","key":"73_CR39","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","volume":"22","author":"RS Herbst","year":"2004","unstructured":"Herbst RS, Giaccone G, Schiller JH et al (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial\u2014INTACT 2. J Clin Oncol 22(5):785\u2013794","journal-title":"J Clin Oncol"},{"key":"73_CR40","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/978-1-4615-0081-0_20","volume":"532","author":"C Manegold","year":"2003","unstructured":"Manegold C (2003) Gefitinib (Iressa, ZD 1839) for non-small cell lung cancer (NSCLC): recent results and further strategies. Adv Exp Med Biol 532:247\u2013252","journal-title":"Adv Exp Med Biol"},{"issue":"11","key":"73_CR41","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1200\/JCO.2003.12.008","volume":"21","author":"VA Miller","year":"2003","unstructured":"Miller VA, Johnson DH, Krug LM et al (2003) Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.J. Clin Oncol 21(11):2094\u20132100","journal-title":"Clin Oncol"},{"issue":"3","key":"73_CR42","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/sj.bjc.6601131","volume":"89","author":"N Magne","year":"2003","unstructured":"Magne N, Fischel JL, Tiffon C et al (2003) Molecular mechanisms underlying the interaction between ZD1839 (\u2018Iressa\u2019) and cisplatin\/5-fluorouracil. Br J Cancer 89(3):585\u2013592","journal-title":"Br J Cancer"},{"key":"73_CR43","unstructured":"Finn RS, Beryt G et al (2002) ZD1839 (Iressa) acts synergistically with chemotherapy in ovarian cancer cells expressing high levels of the epidermal growth factor receptor. Proc Am Soc Clin Oncol 21 (Abstr 1928)"},{"key":"73_CR44","first-page":"2053","volume":"6","author":"F Ciardiello","year":"2000","unstructured":"Ciardiello F, Caputo R, Baino R et al (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053\u20132063","journal-title":"Clin Cancer Res"},{"key":"73_CR45","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1023\/A:1008365716693","volume":"11","author":"T Safra","year":"2000","unstructured":"Safra T, Muggia F, Jeffers S et al (2000) Pegylated liposomal doxorubicin (DOXIL): randomized clinical cardiotoxicity in patients reaching or exceeding cumulative disease of 500\u00a0mg\/m2. Ann Oncol 11:1029\u20131033","journal-title":"Ann Oncol"},{"issue":"3","key":"73_CR46","first-page":"440","volume":"15","author":"ME O\u2019 Brien","year":"2004","unstructured":"O\u2019 Brien ME, Wigler N, Inbar M et al (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic. Breast cancer 15(3):440\u2013449","journal-title":"Breast cancer"},{"issue":"3","key":"73_CR47","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","volume":"15","author":"FM Muggia","year":"1997","unstructured":"Muggia FM, Hainsworth JD, Jeffers S et al (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15(3):987\u2013993","journal-title":"J Clin Oncol"},{"issue":"17","key":"73_CR48","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2000.18.17.3093","volume":"18","author":"AN Gordon","year":"2000","unstructured":"Gordon AN, Granai CO, Rose PG et al (2000) Phase II study of liposomal doxorubicin in platinum and paclitaxel refractory epithelial ovarian cancer. J Clin Oncol 18(17):3093\u20133100","journal-title":"J Clin Oncol"},{"issue":"26","key":"73_CR49","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666\u20132676","journal-title":"N Engl J Med"},{"key":"73_CR50","doi-asserted-by":"crossref","unstructured":"O\u2019Shaughnessy J, Blackwell KL, Burstein H et al (2008) A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2\u00a0+\u00a0metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 26 (May 20 suppl; abstract 1015)","DOI":"10.1200\/jco.2008.26.15_suppl.1015"},{"issue":"2","key":"73_CR51","first-page":"74s","volume":"69","author":"S Johnston","year":"2009","unstructured":"Johnston S, Pegram M, Press M et al (2009) Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF 30008 Trial. Cancer Res 69(2):74s\u201375s Abstract 46","journal-title":"Cancer Res"},{"key":"73_CR52","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000207504","volume":"76","author":"C Christodoulou","year":"2009","unstructured":"Christodoulou C, Kostopoulos I, Kalofonos H et al (2009) Trastuzumab combined with peglyated liposomal doxorubicin in patients with metastatic breast cancer. Oncology 76:275\u2013285","journal-title":"Oncology"},{"key":"73_CR53","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness to non\u2013small lung cancer to gefitinib. N Engl J Med 350:2129\u20132139","journal-title":"N Engl J Med"},{"key":"73_CR54","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497\u20131500","journal-title":"Science"},{"key":"73_CR55","doi-asserted-by":"crossref","unstructured":"Van Cutsem E, Lang I, D\u2019haens G et al (2008) KRAS status and efficacy in the first line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLIRI with and without Cetuximab: the CRYSTAL experience. J Clin Oncol 26 (May 20 suppl; abstract 2)","DOI":"10.1200\/jco.2008.26.15_suppl.2"},{"key":"73_CR56","doi-asserted-by":"crossref","unstructured":"Bokemeyer C, Bondarenko I, Hartmann JT et al (2008) KRAS status and efficacy of first line treatment of patients with metastatic colorectal cancer (cCRC) with FOLFOX with or without cetuximab: the OPUS experience. J Clin Oncol 26 (May 20 suppl; abstract 4000)","DOI":"10.1200\/jco.2008.26.15_suppl.4000"},{"issue":"15","key":"73_CR57","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-05-0462","volume":"11","author":"RJ Schilder","year":"2005","unstructured":"Schilder RJ, Sill MV, Chen W et al (2005) Phase II study of Getinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecological Oncology Group Study. Clin Cancer Res 11(15):5539\u20135548","journal-title":"Clin Cancer Res"},{"key":"73_CR58","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2005.04.8397","volume":"24","author":"MS Gordon","year":"2006","unstructured":"Gordon MS, Matei D, Aghajanian C et al (2006) Clinical activity of pertuzumab (rhuMAb2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predicative relationship between tumor HER 2 activation status. J Clin Oncol 24:4317\u20134323","journal-title":"J Clin Oncol"},{"key":"73_CR59","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1200\/JCO.2005.05.4221","volume":"24","author":"B Tanner","year":"2006","unstructured":"Tanner B, Hasenclever D, Stern K et al (2006) ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 24:4324\u20134332","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-010-0073-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-010-0073-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-010-0073-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T21:07:47Z","timestamp":1591218467000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-010-0073-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,20]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["73"],"URL":"https:\/\/doi.org\/10.1007\/s10147-010-0073-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,20]]}}}